These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28097639)

  • 1. Risk of bleeding and repeated bleeding events in prasugrel-treated patients: a review of data from the Japanese PRASFIT studies.
    Nishikawa M; Isshiki T; Kimura T; Ogawa H; Yokoi H; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    Cardiovasc Interv Ther; 2017 Apr; 32(2):93-105. PubMed ID: 28097639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
    Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
    JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Prasugrel Compared With Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Wang A; Lella LK; Brener SJ
    Am J Ther; 2016; 23(6):e1637-e1643. PubMed ID: 24942006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter research of bleeding risk between prasugrel and clopidogrel in Japanese patients with coronary artery disease undergoing percutaneous coronary intervention.
    Tokimasa S; Kitahara H; Nakayama T; Fujimoto Y; Shiba T; Shikama N; Nameki M; Himi T; Fukushima KI; Kobayashi Y
    Heart Vessels; 2019 Oct; 34(10):1581-1588. PubMed ID: 30944971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
    Gunarathne A; Hussain S; Gershlick AH
    Expert Rev Cardiovasc Ther; 2016 Nov; 14(11):1215-1226. PubMed ID: 27701930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, Double-Blind, Dose-Finding, Phase II Study of Prasugrel in Japanese Patients Undergoing Elective Percutaneous Coronary Intervention.
    Kimura T; Isshiki T; Ogawa H; Yokoi H; Yamaguchi T; Ikeda Y
    J Atheroscler Thromb; 2015; 22(6):557-69. PubMed ID: 25737192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the safety and effectiveness of prasugrel and clopidogrel in younger population undergoing percutaneous coronary intervention: A retrospective study using a Japanese claims database.
    Hagiwara H; Fukuta H; Hashimoto H; Niimura T; Zamami Y; Ishizawa K; Kamiya T; Ohte N
    J Cardiol; 2021 Mar; 77(3):285-291. PubMed ID: 34074484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thienopyridines in Acute Coronary Syndrome.
    Goodwin MM; Desilets AR; Willett KC
    Ann Pharmacother; 2011 Feb; 45(2):207-17. PubMed ID: 21304037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry.
    Kurz DJ; Radovanovic D; Seifert B; Bernheim AM; Roffi M; Pedrazzini G; Windecker S; Erne P; Eberli FR
    Eur Heart J Acute Cardiovasc Care; 2016 Feb; 5(1):13-22. PubMed ID: 25614494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
    Damman P; Varenhorst C; Koul S; Eriksson P; Erlinge D; Lagerqvist B; James SK
    Am J Cardiol; 2014 Jan; 113(1):64-9. PubMed ID: 24169009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
    Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States.
    Larmore C; Effron MB; Molife C; DeKoven M; Zhu Y; Lu J; Karkare S; Lieu HD; Lee WC; Vetrovec GW
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):535-544. PubMed ID: 26577386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No association between on-treatment platelet reactivity and bleeding events following percutaneous coronary intervention and antiplatelet therapy: A post hoc analysis.
    Nishikawa M; Isshiki T; Kimura T; Ogawa H; Yokoi H; Miyazaki S; Ikeda Y; Nakamura M; Takita A; Saito S;
    Thromb Res; 2015 Nov; 136(5):947-54. PubMed ID: 26460279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
    Jackson LR; Ju C; Zettler M; Messenger JC; Cohen DJ; Stone GW; Baker BA; Effron M; Peterson ED; Wang TY
    JACC Cardiovasc Interv; 2015 Dec; 8(14):1880-9. PubMed ID: 26718518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction.
    Lattuca B; Fabbro-Peray P; Leclercq F; Schmutz L; Ledermann B; Cornillet L; Benezet JF; Macia JC; de La Coussaye JE; Messner-Pellenc P; Cayla G
    Arch Cardiovasc Dis; 2016 May; 109(5):337-47. PubMed ID: 27079469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel.
    Bae JP; Faries DE; Ernst FR; Lipkin C; Zhao Z; Moretz C; Lieu HD; Effron MB
    Am J Health Syst Pharm; 2016 Mar; 73(6):395-403. PubMed ID: 26953284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel for Japanese patients with acute coronary syndrome in short-term clinical practice (PRASFIT-Practice I): a postmarketing observational study.
    Nakamura M; Iizuka T; Sagawa K; Abe K; Chikada S; Arai M
    Cardiovasc Interv Ther; 2018 Apr; 33(2):135-145. PubMed ID: 28213685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Arterial Access Route on Bleeding Complications in Japanese Patients Undergoing Percutaneous Coronary Intervention- Insight From the PRASFIT Trial.
    Saito S; Isshiki T; Kimura T; Ogawa H; Yokoi H; Nishikawa M; Miyazaki S; Tanaka Y; Nakamura M;
    Circ J; 2015; 79(9):1928-37. PubMed ID: 26040334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: post-hoc analysis of the randomized PRASFIT-ACS study.
    Nakamura M; Isshiki T; Kimura T; Ogawa H; Yokoi H; Nanto S; Takayama M; Kitagawa K; Ikeda Y; Saito S
    Int J Cardiol; 2015 Mar; 182():541-8. PubMed ID: 25679803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.